AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2639-4162/243
Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, David-Geffen UCLA Medical School, CA, USA.
*Corresponding Author: Nasser Mikhail, Endocrinology Division, Department of Medicine, Olive View-UCLA Medical Center, David-Geffen UCLA Medical School, CA, USA.
Citation: Nasser Mikhail, (2024), Finerenone May Be Added as Standard Care for Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction, J. General Medicine and Clinical Practice, 7(20); DOI:10.31579/2639-4162/243
Copyright: © 2024, Nasser Mikhail. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 22 November 2024 | Accepted: 30 November 2024 | Published: 09 December 2024
Keywords: finerenone; heart failure; cardiovascular events; kidney; finearts-hf; hyperkalemia
The non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone was shown in 2 trials (FIDELIO-DKD and FIAGARO-DKD) to significantly decrease cardiovascular (CV) events and slow progression of kidney function in patients with type 2 diabetes and chronic kidney diseases (CKD). The only medications recommended as first line therapy for patients with heart failure and mildly reduced ejection fraction and preserved ejection fraction (HFmrEF/HFpEF) are the sodium-glucose co-transporters type 2 inhibitors (SGLT-2i). Recently, finerenone was evaluated in patients with HFmr/HFpEF in a trial called the FINEARTS-HF. The latter was a randomized, double-blind, placebo-controlled international trial with the primary composite outcome consisting of first and recurrent (i.e. total) worsening heart failure (HF) events and death from CV causes. Patients included were 40 years or older with left ventricular ejection fraction (LVEF) ≥40%, New York Heart Association (NYHA) functional status, mostly II and III, elevated natriuretic peptides, and evidence of structural heart disease. After a median follow-up of 32 months, 14.9 and 17.7 primary outcome events per 100 patient-year occurred in the finerenone and placebo group, respectively, rate ratio (RR) 0.84 (95% CI, 0.74 to 0.95; P 0.007). The significant reduction in the primary outcome was mainly driven by the reduction in total worsening HF events (RR 0.82; 95% CI 0.71 to 0.94), whereas reduction in CV death did not reach statistical significance RR 0.93 (95% CI, 0.78 to 1.11). Results of secondary outcomes of the FINEART-HF trial showed a trend towards reduction in all-cause death [hazard ratio (HR) 0.93, 95% CI, 0.83 to 1.06)] and worsening of kidney composite outcome HR 1.33 (95% CI, 0.94 to 1.89). There was no heterogeneity in results in different patient subgroups classified by diabetes status, baseline EF, and use of sodium-glucose co-transporters type 2 inhibitors (SGLT-2is). The most common adverse effects of finerenone were hyperkalemia (serum potassium > 5.5 mmol/L) occurring in 14.3% and 6.9% of patients in the finerenone and placebo, groups, respectively. In summary, finerenone is a useful agent for treatment of HFmr/HFpEF that can be added to SGLT2i. Its main limitations are hyperkalemia and possibly worsening kidney function in patients with (HFmr/HFpEF). Long-term studies are required to evaluate the safety of finerenone in patients with (HFmr/HFpEF).
Finerenone (Kerendia) is a non-steroidal MRA approved in patients with type 2 diabetes and CKD to decrease risk of CV events and progression of kidney disease [1]. This approval was based on results of 2 complementary randomized trials, the FIDELIO-DKD and FIGARO-DKD [2,3]. Pooled analysis of the latter 2 trials showed that finerenone significantly decreased the composite CV outcome (time to CV death, non-fatal myocardial infarction and stroke or heart failure hospitalization) by 14% compared with placebo [HR 0.86 (95% CI, 0.78-0.95; P=0.0018)] and the composite kidney outcome (time to kidney failure, sustained ≥57
Primary outcome
The primary outcome of the FINEARTS-HF trial was a composite of total (i.e first and recurrent) worsening HF events (defined as HF requiring admissionto the hospital or urgent care) and death from CV causes. After a median follow-up of 32 months, the number of events per 100 patient-year was 14.9 and 17.7 in the finerenone and placebo groups, respectively RR 0.84 (95% CI, 074 to 0.95; P=0.007) [5]. When analyzed individually, RR for total worsening HF was 0.82 (951 to 0.94; P=0.006), but reduction in death from CV causes did not reach statistical significance with a HR of 0.93 (95% 0.78 to 1.11) [5]. Amelioration in the primary outcome occurred rapidly with the first statistical difference from placebo was observed after 28 days (RR 0.62, 95% CI, 0.40 to 0.97; P=0.037) (9). Interestingly, Desai et al [8] found that risk reductions for the primary outcome tended to be greater among the group of patients enrolled during or within 7 days of worsening HF events (risk ratio 0.74, 95% CI, 0.57to 0.95), then decreased slightly in patients enrolled from 7 days to 3 months from the worsening HF event (risk ratio 0.79; 95% CI, 0.64 to 0.97) to finally disappear in patents enrolled more than 3 months from the worsening HF event (risk ratio 0.99, 95% CI, 0.81 to 1.21) [8].
Secondary outcomes
Finerenone had variable effects on secondary outcomes in the FINEARTS-HF trial. There was mild but significant effect in HF symptoms as evaluated by the Kansas City Cardiomyopathy Questionnaire (KCCQ) total symptom score, difference from placebo being 1.6 (95% CI, 0.8 to 1.15, P<0>Effects of finerenone on kidney outcomes in patients with HFmrEF/HFpEF
In the FINEARTS-HF trial, one secondary outcome was a kidney composite of a sustained decrease in the eGFR of ≥50%, a sustained decline in the eGFR to < 15 n=75) n=55)>Efficacy of finerenone in patient subgroups
The primary outcome results of the FINEARTS-HF were similar in different patient subgroups classified by age, gender, baseline LVEF and kidney function and diabetes status [5]. Approximately 40% of patients in FINEARTS-HF had type 2 diabetes and reduction in the primary outcome was very close in patients with and without type 2 diabetes RR 0.83 and 0.85, respectively [5].
SGLT2 inhibitors
The 2 SGLT2i (empagliflozin and dapagliflozin) are recommended as first line treatment for HF irrespective of ejection fraction based on strong data showing reduction in risk of composite HF hospitalization or CV death [13]. In the FINEARTS-HF trial, 13.6 % (n=817) of patients were treated with a SGLT2i at baseline, mainly dapagliflozin (48.7%, n=406) and empagliflozin (47.2%, n=394) [5,14]. In addition, during follow-up, 980 participants (17.7% and 20.1% in the finerenone and placebo arm, respectively) initiated a SGLT2i [14]. The treatment benefits of finerenone were similar irrespective of concomitant use of SGLT2is. These findings suggest that the combined administration of finerenone and SGLT2i may have additive protective effects against CV events. These observations are also in agreement with a metanalysis by Banerjee et al [15] showing that concomitant use of MRA did not influence the reduction in incidence of the composite of HF hospitalization and CV death. Safety profile of finerenone was not altered with adjunctive therapy with SGLT2 inhibitor [14]. Specifically, although one meta-analysis suggested that SGLT2 inhibitors could attenuate MRA-induced mild hyperkalemia, in FINEARTS-HF trial, the increase in serum potassium levels was 0.19 mmol/L whether patients were receiving or not SGLT2i [14,15].
Pooled analysis of kidney and cardiac trials of finerenone
In a pre-specified analysis called FINE-HEART, Vaduganathan et al [16] pooled results of the three major randomized trials of finerenone in patients with type 2 diabetes and CKD (The FIGARO-DKD and FIDALIO-DKD) and in those with HF-mp/pRF (FINEARTS-HF). The 3 trials included 18,991 patients (mean age 67 years-old, 35% women). The primary outcome of the pooled trials was CV death. After a median follow-up of 2.9 years, CV deaths occurred in 4.4% and 5.0% with finerenone and placebo, respectively. This reduction in CV death did not reach statistical significance; HR 0.89 (95% 0.78 to 1.01; P=0.076) [16]. However, finerenone significantly decreased the risk of CV death when “undetermined” death was added to CV death which occurred in 6.6% and 7.4% with finerenone and placebo, respectively; HR 0.88 (95% CI, 0.79 to 0.98; P=0.025) [16]. Finerenone significantly decreased risk of several important secondary outcomes such as death from any cause (HR 0.91; 95% CI, 0.84 to 0.99; P=0.027), HF hospitalization (HR 0.83, 95% CI, 0.75 to 0.92; P <0 P=0.019)>Safety of finerenone in patients with HFpEF
Hyperkalemia with serum potassium (k) > 6 mmol/L occurred in 3.0% and 1.4% in patients randomized to finerenone and placebo, respectively [5]. Proportions of patients with serum K > 5.5 mmol/L were 14.6% and 7.1% with finerenone and placebo, respectively [5]. Conversely, hypokalemia with serum K < 3>Limitations of finerenone as treatment for HF-mrEF/pEF
While the FINEARTS-HF was multinational, generalizability of its results may be limited since less than 2% were Blacks and proportion of Hispanics in the study was not mentioned [5]. Hyperkalemia was the main safety issue associated with finerenone use with approximately 2-fold higher rates of hyperkalemia when compared to placebo [5]. In real life, incidence of finerenone-induced hyperkalemia is likely to be even higher because patients with serum K > 5 mol/L and eGFR < 25>Clinical implications of the FINEARTS-HF trial
Results of the FINEARTS-HF imply that finerenone should be considered as first line therapy to patients with HFmr/pEF like SGLT2 inhibitors. Available data suggest that clinical benefits of finerenone in patients HF-mr/pEF are not attenuated in presence of concomitant SGLT2 inhibitors. Therefore, until further data become available, finerenone may be added to SGLT2 inhibitors. Regarding the timing of its use, finerenone should be started as early as possible up 3 months from worsening HF to get the maximum clinical benefit as suggested by the analysis of Desai et al [8].
No doubt, finerenone is a useful addition to the management of HFmrEF/HFpEF. In such patients, finerenone significantly decreased total worsening HF events by 16%, whereas the 7% reduction in death from CV causes and death from any cause did not reach statistical significance. Results were similar in subgroups of patients classified by age, gender, diabetes status, baseline EF, and SGLT2 inhibitors use. There was a clear tendency towards greater clinical benefit if finerenone was started within 3 months from the worsening heart failure event. Meanwhile, there was a trend toward worsening kidney function with finerenone. Hyperkalemia was the most common adverse effect of finerenone. Further trials are needed to study the long-term kidney effects of finerenone in subjects with HFmrEF/HFpEF. In addition, to confirm the potential additive beneficial CV effects of finerenone with SGLT2i, randomized trials are required to compare SGLT2i + finerenone with SGLT2i + placebo.
Conflict of interest
The author has no conflict of interest to declare.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
Clinical Cardiology and Cardiovascular Interventions, we deeply appreciate the interest shown in our work and its publication. It has been a true pleasure to collaborate with you. The peer review process, as well as the support provided by the editorial office, have been exceptional, and the quality of the journal is very high, which was a determining factor in our decision to publish with you.
The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews journal clinically in the future time.
Clinical Cardiology and Cardiovascular Interventions, I would like to express my sincerest gratitude for the trust placed in our team for the publication in your journal. It has been a true pleasure to collaborate with you on this project. I am pleased to inform you that both the peer review process and the attention from the editorial coordination have been excellent. Your team has worked with dedication and professionalism to ensure that your publication meets the highest standards of quality. We are confident that this collaboration will result in mutual success, and we are eager to see the fruits of this shared effort.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, I hope this message finds you well. I want to express my utmost gratitude for your excellent work and for the dedication and speed in the publication process of my article titled "Navigating Innovation: Qualitative Insights on Using Technology for Health Education in Acute Coronary Syndrome Patients." I am very satisfied with the peer review process, the support from the editorial office, and the quality of the journal. I hope we can maintain our scientific relationship in the long term.
Dear Monica Gissare, - Editorial Coordinator of Nutrition and Food Processing. ¨My testimony with you is truly professional, with a positive response regarding the follow-up of the article and its review, you took into account my qualities and the importance of the topic¨.
Dear Dr. Jessica Magne, Editorial Coordinator 0f Clinical Cardiology and Cardiovascular Interventions, The review process for the article “The Handling of Anti-aggregants and Anticoagulants in the Oncologic Heart Patient Submitted to Surgery” was extremely rigorous and detailed. From the initial submission to the final acceptance, the editorial team at the “Journal of Clinical Cardiology and Cardiovascular Interventions” demonstrated a high level of professionalism and dedication. The reviewers provided constructive and detailed feedback, which was essential for improving the quality of our work. Communication was always clear and efficient, ensuring that all our questions were promptly addressed. The quality of the “Journal of Clinical Cardiology and Cardiovascular Interventions” is undeniable. It is a peer-reviewed, open-access publication dedicated exclusively to disseminating high-quality research in the field of clinical cardiology and cardiovascular interventions. The journal's impact factor is currently under evaluation, and it is indexed in reputable databases, which further reinforces its credibility and relevance in the scientific field. I highly recommend this journal to researchers looking for a reputable platform to publish their studies.
Dear Editorial Coordinator of the Journal of Nutrition and Food Processing! "I would like to thank the Journal of Nutrition and Food Processing for including and publishing my article. The peer review process was very quick, movement and precise. The Editorial Board has done an extremely conscientious job with much help, valuable comments and advices. I find the journal very valuable from a professional point of view, thank you very much for allowing me to be part of it and I would like to participate in the future!”
Dealing with The Journal of Neurology and Neurological Surgery was very smooth and comprehensive. The office staff took time to address my needs and the response from editors and the office was prompt and fair. I certainly hope to publish with this journal again.Their professionalism is apparent and more than satisfactory. Susan Weiner
My Testimonial Covering as fellowing: Lin-Show Chin. The peer reviewers process is quick and effective, the supports from editorial office is excellent, the quality of journal is high. I would like to collabroate with Internatioanl journal of Clinical Case Reports and Reviews.
My experience publishing in Psychology and Mental Health Care was exceptional. The peer review process was rigorous and constructive, with reviewers providing valuable insights that helped enhance the quality of our work. The editorial team was highly supportive and responsive, making the submission process smooth and efficient. The journal's commitment to high standards and academic rigor makes it a respected platform for quality research. I am grateful for the opportunity to publish in such a reputable journal.
My experience publishing in International Journal of Clinical Case Reports and Reviews was exceptional. I Come forth to Provide a Testimonial Covering the Peer Review Process and the editorial office for the Professional and Impartial Evaluation of the Manuscript.
